INTERVENTIONS TARGETING IMPAIRED FASTING GLUCOSE: A COMPREHENSIVE REVIEW OF STRATEGIES TO PREVENT TYPE 2 DIABETES
Abstract
Objective: Impaired Fasting Glucose (IFG), a state of prediabetes characterized by elevated fasting glucose levels, signifies a significantly increased risk of developing Type 2 Diabetes Mellitus (T2D) and associated cardiovascular complications. This comprehensive review systematically analyzes evidence from original research, including Randomized Controlled Trials (RCTs), prospective and retrospective cohort studies, and single- and multi-center implementation experiences, to evaluate the effectiveness and translation challenges of interventions targeting IFG progression.
Methods: A targeted literature search was conducted across major medical databases, focusing on human intervention studies published between 2000 and 2025. Included articles were categorized based on intervention type (Intensive Lifestyle Intervention [ILI] or pharmacological) and study design, with an emphasis on T2D incidence rate reduction as the primary outcome.
Key Findings: The analysis confirms that ILI, focused on diet, physical activity, and achieving moderate weight loss (5–7%), remains the most efficacious long-term strategy, demonstrating superior and sustained T2D risk reduction (e.g., 58% in the Diabetes Prevention Program) (Diabetes Prevention Program Research Group, 2002); (Tuomilehto et al., 2001). Metformin therapy serves as a critical, cost-effective pharmacological alternative, particularly for high-risk subgroups (e.g., younger individuals, high BMI). Translational studies, including retrospective and multi-center experiences, highlight significant barriers to real-world implementation, such as low sustained adherence and scalability challenges within diverse populations.
Conclusion: Effective T2D prevention in individuals with IFG necessitates early, risk-stratified intervention. While ILI is the gold standard, future strategies must focus on developing tailored, technologically-supported, and scalable programs to overcome implementation barriers and maximize population-level health impact.
References
Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393–403.
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2009). 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet, 374(9702), 1677–1686.
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., & Uusitupa, M. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine, 345(13), 97–103.
Gerstein, H. C., Yusuf, S., Bosch, J., Pogue, J., Sheridan, P., Dinccag, N., Hanefeld, M., Hoogwerf, B., Laakso, M., Mohan, V., Shaw, J., & Stampfer, M. (2007). Effects of acarbose on the risk of myocardial infarction and cardiovascular death in patients with impaired glucose tolerance (STOP-NIDDM): a randomised, double-blind, placebo-controlled trial. The Lancet, 370(9585), 209–217.
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). Xenical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161.
American Diabetes Association. (2024). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2024. Diabetes Care, 47(Supplement 1), S18–S31.
Zheng, Y., Ley, S. H., & Hu, F. B. (2017). Metformin for the Prevention of Type 2 Diabetes in People with Prediabetes: A Systematic Review and Meta-analysis. Diabetes Care, 40(11), 1670–1691.
Blickensderfer, A., Ertl, T. R., & Ertl, D. S. (2019). Effectiveness of a high-intensity, multi-center, community-based diabetes prevention program. Translational Behavioral Medicine, 9(3), 447–455.
Li, R., Qu, S., Zhang, J., Han, X., Chen, C., & Zhang, Y. (2015). Interventions to prevent type 2 diabetes in high-risk populations: A systematic review and meta-analysis. Diabetes Care, 38(9), 1600–1610.
Lim, S., Lee, M. K., Park, H. S., Park, J. H., Lee, J. G., & Kim, C. H. (2021). Effect of a structured lifestyle intervention on preventing the progression of prediabetes: A retrospective single-center experience. Journal of Clinical Endocrinology & Metabolism, 106(4), e1998–e2007.
Poggio, R., Zoppini, G., & Santi, L. (2020). Preventing Type 2 Diabetes in Clinical Practice: One-Center Experience Using a Personalized Approach. International Journal of Endocrinology, 2020, 5327854.
Shelton, D., Davies, K., & Smith, J. (2013). Effectiveness of the diabetes prevention program in an integrated health care setting: A retrospective cohort study. American Journal of Managed Care, 19(10), e363–e371.
Copyright (c) 2026 Marzena Swojnóg, Zuzanna Dobrakowska, Radosław Swędrak, Jakub Klepacz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
